Disclosure Of First-Time Adoption [Text Block]

Innate Pharma - Filing #2811003

Concept	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31
Disclosure of first-time adoption [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [abstract]
Disclosure of comparative information prepared under previous GAAP [line items]
Equity	495,000 EUR	—	—	51 901 EUR	329 323 EUR	7 570 EUR	—	—	—	—	—	384 255 EUR	—	4 044 EUR	54 151 EUR	—	—	819,000 EUR	—	58 103 EUR	—	—	—	379 637 EUR	272 213 EUR	4 011 EUR	—	—	219 404 EUR	107 440 EUR	52 809 EUR	456,000 EUR	375 220 EUR	3 978 EUR
Comprehensive income	—	6 900 EUR	324,000 EUR	—	—	—	7 570 EUR	994,000 EUR	— EUR	— EUR	— EUR	—	— EUR	—	—	— EUR	57 741 EUR	—	— EUR	—	58 103 EUR	— EUR	— EUR	—	—	—	362,000 EUR	— EUR	—	—	—	—	—	—
Profit (loss)	—	7 570 EUR	— EUR	—	—	—	7 570 EUR	— EUR	— EUR	— EUR	— EUR	—	— EUR	—	—	— EUR	58 103 EUR	—	— EUR	—	58 103 EUR	— EUR	— EUR	—	—	—	— EUR	— EUR	—	—	—	—	—	—